The Type 2 Diabetes Pipeline report provides a thorough commercial and clinical evaluation of pipeline products, spanning from pre-clinical development to market availability. It includes a comprehensive overview of each drug, encompassing its mechanism of action, clinical studies, potential NDA approvals, and various product development aspects such as technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details.
“Type 2 Diabetes Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 2 Diabetes Market.
Some of the key takeaways from the Type 2 Diabetes Pipeline Report:
Companies across the globe are diligently working toward developing novel Type 2 Diabetes treatment therapies with a considerable amount of success over the years.
Type 2 Diabetes companies working in the treatment market are Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd., Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co, Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others, are developing therapies for the Type 2 Diabetes treatment
Emerging Type 2 Diabetes therapies in the different phases of clinical trials are- Research programme-type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others are expected to have a significant impact on the Type 2 Diabetes market in the coming years.
In June 2023, Pfizer Inc. declared its intention to advance a specific oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate further into clinical development for potential use in treating adults with obesity and Type 2 diabetes mellitus (T2DM). The company will proceed with advancing the clinical program for danuglipron (PF-06882961), contingent upon the outcomes from the ongoing Phase 2 trial.
In January 2023, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical enterprise concentrating on oral drug delivery systems, revealed key findings from its Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) assessing the effectiveness of ORMD-0801 compared to placebo in individuals with Type 2 Diabetes (T2D) over a 26-week period.
Type 2 Diabetes Overview
Diabetes is a long-term metabolic disorder marked by fluctuations in blood glucose (blood sugar) levels. Over time, diabetes can cause serious harm to the heart, blood vessels, eyes, kidneys, nerves, and blood vessels.
Get a Free Sample PDF Report to know more about Type 2 Diabetes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight
Emerging Type 2 Diabetes Drugs Under Different Phases of Clinical Development Include:
Research programme: type 2 diabetes mellitus therapeutics Abarceo Pharma
NRDN-101: Neurodon
ECC5004: Eccogene
KN056: Suzhou Alphamab Co., Ltd.
XW014: Sciwind Biosciences
RGT001-075: Regor Pharmaceuticals
HR17031: Jiangsu Hengrui Medicine Co.
CPL207280: Celon Pharma
THDB0206: Tonghua Dongbao Pharmaceutical
LY-3209590: Eli Lilly and Company
Insulin icodec: Novo Nordisk
AMG 133: Amgen
HR17031: Jiangsu Hengrui Medicine Co
CT996: Carmot Therapeutics
ORMD-0801: Oramed Pharmaceuticals
Type 2 Diabetes Route of Administration
Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type
Type 2 Diabetes Molecule Type
Type 2 Diabetes Products have been categorized under various Molecule types, such as
Oligonucleotide
Peptide
Small molecule
Product Type
Type 2 Diabetes Pipeline Therapeutics Assessment
Type 2 Diabetes Assessment by Product Type
Type 2 Diabetes By Stage and Product Type
Type 2 Diabetes Assessment by Route of Administration
Type 2 Diabetes By Stage and Route of Administration
Type 2 Diabetes Assessment by Molecule Type
Type 2 Diabetes by Stage and Molecule Type
DelveInsight’s Type 2 Diabetes Report covers around 100+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Type 2 Diabetes product details are provided in the report. Download the Type 2 Diabetes pipeline report to learn more about the emerging Type 2 Diabetes therapies
Some of the key companies in the Type 2 Diabetes Therapeutics Market include:
Key companies developing therapies for Type 2 Diabetes are – Novo Nordisk, Jiangsu Hengrui Medicine, Melior Pharmaceuticals, Adocia, Pfizer, AgeX Therapeutics, CarmotTherapeutics, Genexine, Inc., OPKO Health, Inc., VitNovo, Inc., Sciwind Biosciences, Caelus Health, SCOHIA PHARMA, Ionis Pharmaceuticals, Eli Lilly and Company, Oramed Pharmaceuticals, AstraZeneca, Aerami Therapeutics, Viking Therapeutics, VTV Therapeutics, AptamiR Therapeutics, Avolynt, Inc., Suzhou Yabao Pharmaceutical, CONJUCHEM, LLC., Hua Medicine, REMD Biotherapeutics, Novmeta Pharma, Afimmune Limited, Xeris Pharmaceuticals, Akros Pharma Inc., and others.
Type 2 Diabetes Pipeline Analysis:
The Type 2 Diabetes pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.
Type 2 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Type 2 Diabetes drugs and therapies
Type 2 Diabetes Pipeline Market Drivers
Increasing Prevalence, government bodies are collaborating with major market players for the launch of new products, increase in the demand for insulin over the world are some of the important factors that are fueling the Type 2 Diabetes Market.
Type 2 Diabetes Pipeline Market Barriers
However, side-effects associated with the treatment of Type 2 Diabetes, a lack of knowledge about a healthy diet, medication initiation and other factors are creating obstacles in the Type 2 Diabetes Market growth.
Scope of Type 2 Diabetes Pipeline Drug Insight
Coverage: Global
Key Type 2 Diabetes Companies: Abarceo Pharma, Carmot Therapeutics, Neurodon, Eccogene, Suzhou Alphamab Co., Ltd., Sciwind Biosciences, Amgen, Regor Pharmaceuticals, Jiangsu Hengrui Medicine Co, Celon Pharma, Oramed Pharmaceuticals, Eli Lilly and Company, Novo Nordisk, and others
Key Type 2 Diabetes Therapies: Research programme-type 2 diabetes mellitus therapeutics, CT996, NRDN-101, ECC5004, KN056, XW014, AMG 133, RGT001-075, HR17031, CPL207280, ORMD-0801, LY-3209590, Insulin icodec, and others
Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies
Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers
Request for Sample PDF Report for Type 2 Diabetes Pipeline Assessment and clinical trials
Table of Contents
1. Type 2 Diabetes Report Introduction
2. Type 2 Diabetes Executive Summary
3. Type 2 Diabetes Overview
4. Type 2 Diabetes- Analytical Perspective In-depth Commercial Assessment
5. Type 2 Diabetes Pipeline Therapeutics
6. Type 2 Diabetes Late Stage Products (Phase II/III)
7. Type 2 Diabetes Mid Stage Products (Phase II)
8. Type 2 Diabetes Early Stage Products (Phase I)
9. Type 2 Diabetes Preclinical Stage Products
10. Type 2 Diabetes Therapeutics Assessment
11. Type 2 Diabetes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Type 2 Diabetes Key Companies
14. Type 2 Diabetes Key Products
15. Type 2 Diabetes Unmet Needs
16 . Type 2 Diabetes Market Drivers and Barriers
17. Type 2 Diabetes Future Perspectives and Conclusion
18. Type 2 Diabetes Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
